本研究探讨非清髓异基因造血干细胞移植(non-myeloablative allogeneic stem cell transplantation,NAST)治疗血液病时急性移植物抗宿主病(aGVHD)的发生情况及临床特点。 2.
基于4个网页-相关网页
Conclusion: Allogeneic peripheral blood stem cell non-myeloablative transplantation can be selectively used in the treatment of metastasis breast cancer.
结论：异基因非清髓性外周血干细胞移植可选择性地应用于晚期乳腺癌的治疗。
Post non myeloablative allogeneic stem cell transplantation (NST) patients usually received DLI one times a month, consecutively 1 ~ 4 times.
非去髓性异基因干细胞移植(nst)患者通常在移植后每月输注1次，连续1 ~ 4次。
The aim of this study was to analyze the hematopoietic chimerism after non-myeloablative allogeneic peripheral blood stem cell transplantation (NAPBSCT).
本研究旨在探讨非清髓异基因外周血造血干细胞移植(NAPBSCT)后造血嵌合体的临床意义。
应用推荐